Overview

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Status:
Terminated
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Taiwan Liposome Company